You searched for "VEGF"
Intravitreal functional plasminogen in branch retinal vein occlusion
1 December 2014
| Bheemanagouda Patil
|
EYE - Vitreo-Retinal
Branch retinal vein occlusion (BRVO) is the second most common vascular disorder of the eye. Intravitreal injections of anti-VEGF agents and corticosteroids have proven efficacy. Posterior vitreous cortex (PVC) adhesion has been shown to support the development of retinal vein...
International variations in ROP treatment
1 August 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...
Effect of single intravitreal injection of bevacizumab on contrast sensitivity in patients with central retinal vein occlusion
Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. There are many studies reporting the efficacy of intravitreal anti-VEGF injections for macular oedema secondary to retinal vein occlusions. This paper looks at the contrast...
The global burden of age-related macular degeneration
1 October 2019
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the third leading cause of blindness (behind cataract and refractive error). The authors present the results of the Global Burden of Disease (GBD) 2015 study, which included 195 countries. The disability-adjusted life years (DALY) due...
FA findings in treatment-naive premature infants
This retrospective study examined fluorescein angiography (FA) images of 162 eyes of 81 treatment-naive infants with retinal vascular immaturity and persistent avascular retina (PAR) despite exceeding postmenstrual age of 60 weeks. Disc diameter (DD), optic disc-to-fovea distance (FD), the length...
Long-term treatment for diabetic macular oedema
2 April 2025
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...
Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
2 August 2024
| Rod McNeil
|
EYE - General
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...
Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Treatment of diabetic macular oedema
1 June 2014
| Samantha S Mann
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
Progress in retinal disease management: Highlights of the Retina Day, RCOphth 2025 Annual Congress
4 August 2025
| Rod McNeil
|
EYE - Vitreo-Retinal
The Retina Day meeting at the Royal College of Ophthalmologists (RCOphth) 2025 Annual Congress in Liverpool was held on 22 May 2025. This report highlights 10 selected topics of interest to subspecialists and general ophthalmologists. Decarbonising anti-VEGF clinics (or making...
Intravitreal afibercept and ranibizumab for PCV
1 August 2016
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...
